Therapy Areas: Cardiovascular
Takeda divests select OTC and non-core assets for USD660m
4 March 2020 -

Biopharmaceutical company Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) disclosed on Tuesday the completion of the divestiture of a portfolio of select products to STADA Arzneimittel AG (STADA) for a total value of USD660m.

This portfolio includes approximately 20 over-the-counter (OTC) and prescription pharmaceutical products exclusively in Russia, Georgia as well as a number of countries within the Commonwealth of Independent States.

Takeda added that the portfolio includes OTC Vitamins and Food Supplements, plus select products within the Cardiovascular, Diabetes, General Medicine and Respiratory therapeutic areas.

Under a manufacturing and supply agreements, Takeda will continue to manufacture and supply the products to STADA. The portfolio's growth is driven by sales of Cardiomagnyl and other strong regional brands.

As part of the agreement, approximately 450 employees from Takeda supporting the divested assets have transitioned over to STADA.

Login
Username:

Password: